Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP challenge

01-05-2014


Article by:

A. Patterson, B. Fergen, J. Hermann, G. Haiwick and R. Philips. Boehringer Ingelheim Vetmedica Inc. 2014. 

The use of Ingelvac PRRS® vaccines can significantly reduce lung lesions following challenge with heterologous isolates (86-94% ORF5 nucleotide similarity) in the three-week-old pig respiratory challenge model. However, the efficacy of Ingelvac PRRS® MLV vaccine against current virulent PRRSV isolates, such as RFLP 1-7-4, has not been reported to date.

This experiment was designed to evaluate the efficacy of two commercially available PRRSV vaccines in a three-week-old pig respiratory challenge model, using a heterologous RFLP 1-7-4 field isolate from 2014.

Share